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OBJECTIVE— To determine the longitudinal association of components of health-related
functioning (HRF) with incident impaired glucose metabolism and type 2 diabetes.
RESEARCH DESIGN AND METHODS— The Australian Diabetes Obesity and Life-
style (AusDiab) study is a national, longitudinal study of adults aged 25 years from 42 ran-
domly selected areas of Australia. Diabetes status was defined using the World Health
Organization criteria, and HRF was assessed using the SF-36 questionnaire in 1999–2000 and
2004–2005.
RESULTS— Incident impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and
newly diagnosed type 2 diabetes were associated with increased bodily pain at baseline com-
pared with those with normal glucose tolerance (NGT) (IFG P  0.005, IGT P  0.004, and
newly diagnosed type 2 diabetes P 0.005), after adjustment. In addition, those with incident
IGT and newly diagnosed type 2 diabetes had significantly reduced physical functioning, general
health, mental health, and vitality at baseline compared with those with NGT. After we con-
trolled for factors associated with incident diabetes, those in the lowest quartile of the physical
component summary scale at baseline had at least a 50% higher risk of progression to impaired
glucose metabolism and diabetes 5 years later.
CONCLUSIONS— These findings show that incident IFG, IGT, and newly diagnosed type
2 diabetes are associated with reduced HRF independent of cardiovascular disease and that this
is evident before the onset of these conditions. If future health promotion campaigns are to
effectively target those at high risk of developing diabetes, an understanding of the process of
declining health before onset of the disease is essential.
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The prevalence of type 2 diabetes isincreasing rapidly throughout theworld. The difficulties in curbing
this trend make it vital that we fully un-
derstand all aspects of the disease process.
Although traditional risk factors for type 2
diabetes have been extensively studied,
the role of components of health-related
functioning (HRF), an important compo-
nent of health (1), has not fully been ex-
plored in contemporary, population-
based studies.
There is now growing evidence to
suggest that HRF, which reflects a mea-
sure of physical, social, and mental health
functioning, may be impaired before the
onset of type 2 diabetes (2). A small num-
ber of cross-sectional studies have sug-
gested that those with impaired fasting
glucose (IFG) and or impaired glucose
tolerance (IGT) have reduced HRF com-
pared with those with normal glucose tol-
erance (NGT) on a number of the SF-36
dimensions (3–5). Although many stud-
ies have previously shown that individu-
als with diabetes-related complications
have reduced HRF compared with those
without complications (6,7) and several
studies have shown that HRF is impaired
among those with diabetes compared
with those without diabetes (8,9), little is
known about the stage of the disease at
which HRF becomes impaired. This is im-
portant to establish if a holistic approach
to health care is to be taken, and we are to
fully understand the etiology and patho-
genesis of the disease.
An understanding of how some psy-
chosocial factors directly impact the de-
velopment of type 2 diabetes and other
chronic diseases is already beginning to
emerge. Psychosocial stress, for example,
is known to increase the inflammatory
process (10,11) and has been linked di-
rectly with accelerated atherosclerosis
(10), myocardial ischemia (12), and inci-
dent type 2 diabetes (2). This finding sug-
gests that psychosocial risk factors are
likely to be important to consider in the
identification of individuals at high risk of
developing type 2 diabetes, as well as in
interventions to prevent diabetes. The
Australian Diabetes, Obesity and Lifestyle
(AusDiab) study, with its large, national,
population-based sample, with 5 years of
follow-up, provides an ideal setting in
which to investigate the association of
HRF with the subsequent development of
impaired glucose metabolism and type 2
diabetes.
RESEARCH DESIGN AND
METHODS— The population, meth-
ods and response rates of the AusDiab
study are detailed elsewhere (13,14). In
brief, the AusDiab study was a popula-
tion-based study of 11,247 individuals
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aged 25 years, from 42 randomly se-
lected urban and rural areas of Australia,
conducted in 1999–2000. At baseline,
55.3% (n  11,247) of those completing
a household questionnaire undertook the
full survey, and the follow-up response
rate in 2004–2005 was 60.6% (6,537 OF
10,788). There were 459 who were ineli-
gible for the follow-up study because of a
terminal illness, death or refusal of further
contact. The study was approved by the
ethics committee of the International Di-
abetes Institute. Informed consent for the
study was obtained from all participants.
Diabetes classification was based on
plasma glucose results, using the 1999
World Health Organization diabetes clas-
sification (15). Diabetes was diagnosed on
the basis of fasting plasma glucose of
7.0 mmol/l or 2-h plasma glucose of
11.1 mmol/l or current treatment with
insulin or oral hypoglycemic medication.
Those with self-reported diabetes, those
receiving current treatment (insulin or
oral hypoglycemic medication), and
those with diabetic glucose values at base-
line were categorized as having known di-
abetes and were excluded from this study.
Newly diagnosed diabetes was defined as
participants in whom diabetes was diag-
nosed through the AusDiab study. Inci-
dent newly diagnosed diabetes (incident
diabetes) at 5 years was defined as partic-
ipants without known diabetes or newly
diagnosed diabetes at baseline in whom
diabetes was diagnosed by the follow-up
examination (n 224). Incident IGT and
IFG were defined at 5 years as participants
with NGT at baseline in whom IGT or IFG
was diagnosed at the 5-year follow-up ex-
amination (n  432). Only those with
NGT at baseline and follow-up (n 
4,225) were included in the comparison
group for the analyses focused on catego-
ries of glucose metabolism. For these
analyses, complete data were available on
key variables of interest for 200 with in-
cident newly diagnosed diabetes, 257
with incident IGT, 137 with incident
IFG, and 3,906 who maintained NGT
throughout. For the analysis focused on
those with and without incident newly di-
agnosed diabetes, those with IFG and IGT
at baseline were also included.
In 1999–2000, fasting plasma glu-
cose (FPG) and 2-h plasma glucose levels
were determined by the glucose oxidase
method using an Olympus AU600 au-
tomated analyzer (Olympus Optical,
Tokyo, Japan), and in 2004 –2005, a
spectrophotometric hexokinase method
using a Roche Modular analyzer (Roche
Diagnostics, Indianapolis, IN) was used.
Remeasurement of stored baseline sam-
ples with the assay used at follow-up
showed good agreement between the two
assays (14). Serum triglycerides, total
cholesterol, and HDL cholesterol were
measured by enzymatic methods at base-
line. High-performance liquid chroma-
tography (Bio-Rad Variant Hemoglobin
Testing System; Bio-Rad Laboratories,
Hercules, CA) was used for glycated he-
moglobin analysis with standardized con-
version to A1C values (normal range
4.2– 6.3%). C-peptide was measured
by radioimmunoassay with human C-
peptide kits (Linco, St. Charles, MO).
Blood pressure was measured using a Di-
namap monitor or a standard mercury
sphygmomanometer. To account for any
effect due to differential measurement
error, manual blood pressure mea-
surements were adjusted as described
previously (16). Hypertension was de-
fined as present if systolic blood pressure
was140 mmHg or diastolic blood pres-
sure was 90 mmHg or the participant
reported current treatment for hyperten-
sion. Height and weight were measured
with the subject in light clothing by a
trained observer. BMI was calculated as
weight in kilograms divided by the square
of height in meters. Information on smok-
ing, medications, and history of diabetes
were obtained by interview.
Components of social functioning
were assessed using version 1 of the SF-36
Quality of Life Scale (17). The SF-36
(http://www.sf-36.org/tools/sf36.shtml)
is a self-administered measure of per-
ceived health status over the past week,
comprising eight domains: physical func-
tioning, role-physical, bodily pain, gen-
eral health, vitality, social functioning,
role-emotional, and mental health. Items
for each dimension are coded, summed,
and translated from worst health (0) to
best health (100). Physical functioning re-
fers to the ability to perform activities
(walking, climbing stairs, bending and
stretching, and lifting and carrying ob-
jects) without limitation. Role limitation
(physical) refers to the limitations that re-
duced physical health has on the range
and extent of physical activities one is able
to perform. Bodily pain refers to the se-
verity of pain and its impact on daily ac-
tivities. General health is a rating of one’s
own health, a comparison with others’
health, and proneness to illness. Vitality
refers to how energetic or tired an indi-
vidual feels. Social functioning refers to
the impact of physical and emotional
health on the ability to perform normal
social activities. Role limitation (emo-
tional) refers to limitations that emotional
problems put on the range and extent of
activities one could perform. Mental
health refers to the degree of nervousness
or calmness and happiness or sadness.
In addition, the survey established
scores for two summary measures: Phys-
ical Component Summary (PCS) and
Mental Health Component Summary
(MCS) (17). The PCS is a summary of
physical functioning, role-physical,
bodily pain, and general health. The MCS
is a summary measure of vitality, social
functioning, role-emotional, and mental
health. Both PCS and MCS are compo-
nents of health that have been shown to
be useful and valid measures of mental
and physical health functioning relative to
health profile. Overall, the SF-36 has been
widely used in studies of chronic disease.
Statistical methods
Statistical analysis was performed us-
ing SPSS (version 14.0 for Windows,
2005; SPSS, Chicago, IL). Descriptive
information for each of the variables
was derived and distribution was as-
sessed. Univariate associations between
each dimension of the SF-36 scale and
other variables of interest were assessed
using ANOVA for metric variables and a
2 test for categorical variables. Two mul-
tivariate models (ANCOVA), applied sep-
arately to each SF-36 scale allow tiered
analysis of the effect of diabetes status on
quality-of-life measures. Model 1 was ad-
justed for age and sex only. Model 2
added three further important factors to
model 1: systolic blood pressure, BMI,
and total cholesterol. Model 3 included
SF-36 dimensions adjusted for model 2
and smoking, known cardiovascular dis-
ease (CVD), and medication for hyperten-
sion or a lipid abnormality. Marginal
means are presented for each model, rep-
resenting the mean values for each SF-36
scale after adjustment for covariates. P 
0.05 was considered statistically signifi-
cant. The risk of being in the lowest quar-
tile (i.e., poor quality of life) of each
summary measure (physical and mental
component of health) was assessed using
logistic regression.
RESULTS— The characteristics of the
population according to glucose tolerance
status at outcome are shown in Table 1.
Across categories of glucose metabolism,
there were significant differences in age,
systolic and diastolic blood pressure, cho-
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lesterol, triglycerides, glycemic measures,
waist circumference, and BMI.
Incident diabetes at follow-up was as-
sociated with significantly lower mean
baseline scores on each of the eight SF-36
dimensions compared with those who re-
mained in the NGT category, adjusted for
age and sex (physical functioning, role-
physical, bodily pain, general health, vi-
tality, social functioning, role-emotional,
and mental health) (Table 2). These dif-
ferences were only partially attenuated by
adjustment for BMI, systolic blood pres-
sure, and total cholesterol at baseline.
Further adjustment for known CVD,
smoking, lipid abnormality, and hyper-
tension reduced the mean values of each
dimension but did not greatly alter the
association.
Among those with incident IGT at fol-
low-up, baseline scores for physical
functioning, role-physical, bodily pain,
general health, vitality, social functioning,
and mental health were significantly
lower compared with scores for those
with NGT (after adjustment for age and
sex). These differences in physical func-
tioning, bodily pain, general health, vital-
ity, and mental health were only partially
attenuated by adjustment for systolic
blood pressure, BMI, and total choles-
terol. Further adjustment for known
CVD, smoking, lipid abnormality, and
hypertension reduced the mean values of
each dimension but did not significantly
alter the association. Among those with
incident IFG at follow-up, baseline scores
for Physical Functioning, Role-Physical,
and Bodily Pain were significantly lower
compared with scores for those with
NGT. However, after further adjustment
for BMI, systolic blood pressure, and total
cholesterol at baseline only the difference
for Bodily Pain remained. Further adjust-
ment for known CVD, smoking, lipid ab-
normality, and hypertension reduced the
mean values of each dimension but did
not significantly alter the association.
Further inclusion of baseline FPG in a
fifth model failed to attenuate the associ-
ations observed for each dimension of the
SF-36 (data not shown). A final model
comparing those with and without inci-
dent diabetes (using all available data, n
5,450) made no difference to the associa-
tion of diabetes with impaired quality of
life on the physical functioning, bodily
pain, general health, social functioning,
and role-emotional dimensions (after
adjustment for age, sex, BMI, total cho-
lesterol, smoking, known CVD, and
medication for hypertension or a lipid ab-
normality. Results were as follows
(mean  SEM): for physical functioning,
no diabetes 78.5  0.6 and diabetes
74.9 1.2 (P 0.002); for role-physical,
no diabetes 75.9  1.1 and diabetes
71.9  2.4 (P  0.070); for bodily pain,
no diabetes 71.6  0.8 and diabetes
68.4  1.6 (P  0.043); for general
health, no diabetes 64.7 0.6 and diabe-
tes 61.2 1.3 (P 0.004); for vitality, no
diabetes 59.3  0.7 and diabetes 57.0 
1.5 (P 0.104); for social functioning, no
diabetes 84.6  0.7 and diabetes 81.0 
1.4 (P  0.006); for role-emotional no
diabetes 82.1  1.1 and diabetes 77.9 
2.3 (P 0.051); and for mental health, no
diabetes 74.8  0.6 and diabetes 72.8 
1.2 (P  0.096).
The physical functioning summary
score showed a significant gradual de-
crease across categories of glucose metab-
olism from NGT through to incident
diabetes (Fig. 1). After we controlled for
factors associated with incident diabetes,
those in the lowest quartile of the PCS
scale at baseline had at least a 50% higher
risk of progression to impaired glucose
metabolism and diabetes 5 years later
(IFG odds ratio 1.7 [95% CI 1.2–2.5],
IGT 1.5 [1.1–2.1], and newly diagnosed
diabetes 1.5 [1.1–2.1]). An association
only with NDM was evident for the MCS
measure.
CONCLUSIONS— There were three
principal findings in this national, popu-
lation-based study from Australia. First,
those with incident IFG had increased
bodily pain before the onset of IFG
(model 2). Second, those with IGT had
increased bodily pain and reduced phys-
ical functioning, general health, vitality,
and mental health before the onset of IGT.
Third, those with incident newly diag-
nosed diabetes had impaired HRF on each
dimension of the SF-36 before the onset
Table 1—Baseline population characteristics of the AusDiab study participants according to diabetes status at the 5-year follow-up
Analysis of incident IFG/IGT Analysis of incident diabetes
NGT 1999
and 2005 Incident IFG Incident IGT P
Nondiabetic 1999
and 2005*
Incident
diabetes P
n 3,906 137 257 5,171 200
Age (years) 49  12 51  10 55  13 0.001 51  12 55  12 0.001
Sex (male) 43 58 44 0.003 45 52 0.050
FPG (mmol/l) 5.2  0.4 5.6  0.3 5.4  0.4 0.001 5.4  0.5 5.9  0.6 0.001
2-h plasma glucose (mmol/l) 5.4  1.1 5.7  1.2 6.2  1.0 0.001 5.8  1.5 5.9  1.8 0.001
BMI (kg/m²) 25.9  4.3 28.8  4.6 28.1  5.0 0.001 26.5  4.6 29.6  5.6 0.001
Waist circumference (cm) 87.4  12.7 97.5  11.8 94.3  12.9 0.001 89.4  13.2 98.9  14.6 0.001
Lipid treatment (%) 6 7 8 0.001 7 16 0.001
HDL cholesterol (mmol/l) 1.5  0.4 1.3  0.3 1.4  0.4 0.001 1.5  0.4 1.3  0.4 0.001
Total cholesterol (mmol/l) 5.6  1.0 5.8  0.9 5.9  1.1 0.001 5.6  1.0 5.9  1.0 0.001
Triglycerides (mmol/l) 1.1 (0.8–1.6) 1.4 (1.0–2.2) 1.5 (1.1–2.2) 0.001 1.2 (0.8–1.7) 1.7 (1.2–2.5) 0.001
Current smoker (%) 12 10 11 0.730 11 15 0.075
Hypertension (%) 22 31 42 0.001 27 54 0.001
Systolic blood pressure (mmHg) 125  16 131  17 133  19 0.001 127  17 137  18 0.001
Diastolic blood pressure (mmHg) 69  11 73  11 71  12 0.001 70  11 75  12 0.001
Data are mean SD unless otherwise indicated. Those with NGT had normal glucose tolerance at baseline and follow-up. Those included with incident IFG or IGT
had NGT at baseline. Those with incident diabetes were free of diabetes at baseline and had a diagnosis of newly diagnosed diabetes at follow-up. Only those with
complete data on variables modeled are included. *Includes those with IFG or IGT at baseline or follow-up.
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of type 2 diabetes. These are important
findings. The impact of HRF on subse-
quent development of incident impaired
glucose metabolism and type 2 diabetes,
as far as we are aware, has not previously
been explored in a large national represen-
tative population-based sample. The identi-
fication of impaired HRF factors before the
onset of impaired glucose metabolism
and newly diagnosed diabetes suggests
that HRF is likely to be important in the
identification of individuals at high risk of
type 2 diabetes.
Our study results can be compared
with the few population-based studies
available (3,4). In a cross-sectional Aus-
tralian study of 4,060 individuals, those
with IFG had significantly worse scores
for physical functioning and bodily pain
than those with NGT (after adjustment for
age, sex, and cardiovascular disease) (4).
Although the AusDiab cross-sectional
study showed no impairment in HRF
among those with IFG compared with
those with NGT, those with IGT had im-
paired physical and social functioning
compared with those with NGT (after ad-
justment for age, sex, BMI, physical activ-
ity, and treatment for hypertension or a
lipid abnormality) (5). In a study by Hil-
tunen et al. (3), a pattern of general wors-
ening of HRF across categories of glucose
tolerance status was evident. However,
because of the limited sample size, no
firm conclusions could be drawn. In the
present study, those with incident newly
diagnosed diabetes had worse scores on
all SF-36 dimensions apart from mental
health and vitality compared with those
with NGT (model 3). This result is very
similar to the findings of the study by
Chittleborough et al. (4), who showed
Table 2—Adjusted mean values of baseline SF-36 dimensions according to glucose tolerance status at 5 years: the AusDiab study
SF-36 dimension and diabetes status Model 1* P Model 2† P Model 3‡ P
Physical functioning
NGT 1999 and 2005 86.5  0.3 Ref 86.2  0.3 Ref 79.7  0.7 Ref
Incident IFG 83.0  1.4 0.010 85.1  1.3 0.424 78.5  1.5 0.349
Incident IGT 82.7  1.0 0.001 84.2  1.1 0.048 78.1  1.2 0.087
Incident newly diagnosed diabetes 78.2  1.1 0.001 81.1  1.1 0.001 75.6  1.2 0.001
Role limitation physical
NGT 1999 and 2005 84.8  0.5 Ref 84.6  0.5 Ref 76.8  1.4 Ref
Incident IFG 78.5  2.6 0.017 79.7  2.6 0.066 71.8  2.9 0.057
Incident IGT 80.5  1.9 0.031 81.3  1.9 0.099 73.9  2.3 0.141
Incident newly diagnosed diabetes 77.0  2.2 0.001 78.6  2.2 0.007 71.8  2.4 0.027
Bodily pain
NGT 1999 and 2005 76.8  0.3 Ref 76.6  0.3 Ref 75.6  1.0 Ref
Incident IFG 69.9  1.8 0.001 71.4  1.8 0.005 67.3  2.0 0.004
Incident IGT 71.6  1.3 0.001 72.6  1.3 0.004 68.8  1.6 0.006
Incident newly diagnosed diabetes 70.3  1.5 0.001 72.2  1.5 0.005 68.8  1.7 0.015
General health
NGT 1999 and 2005 73.5  0.3 Ref 73.3  0.3 Ref 65.2  0.8 Ref
Incident IFG 71.7  1.5 0.234 73.2  1.5 0.953 64.9  1.6 0.819
Incident IGT 66.3  1.2 0.001 67.4  1.1 0.001 59.7  1.3 0.001
Incident newly diagnosed diabetes 65.6  1.5 0.001 68.8  1.5 0.001 60.9  1.4 0.001
Vitality
NGT 1999 and 2005 64.4  0.3 Ref 64.3  0.3 Ref 59.7  0.9 Ref
Incident IFG 62.8  1.6 0.335 64.0  1.6 0.881 59.3  1.8 0.814
Incident IGT 60.4  1.2 0.001 61.2  1.2 0.012 56.8  1.4 0.020
Incident newly diagnosed diabetes 59.4  1.4 0.001 60.9  1.4 0.017 57.1  1.5 0.061
Social functioning
NGT 1999 and 2005 89.5  0.3 Ref 89.4  0.3 Ref 86.1  0.8 Ref
Incident IFG 87.0  1.5 0.105 87.5  1.5 0.229 84.1  1.7 0.217
Incident IGT 87.0  1.1 0.035 87.4  1.1 0.078 84.1  1.4 0.099
Incident newly diagnosed diabetes 83.8  1.3 0.001 84.5  1.3 0.001 81.5  1.5 0.001
Role-emotional
NGT 1999 and 2005 86.5  0.5 Ref 86.5  0.5 Ref 84.2  1.4 Ref
Incident IFG 83.0  2.5 0.153 83.8  2.5 0.294 81.5  2.8 0.280
Incident IGT 83.7  1.8 0.128 84.3  1.8 0.243 82.1  2.2 0.261
Incident newly diagnosed diabetes 79.8  2.1 0.001 80.8  2.1 0.008 78.9  2.4 0.014
Mental health
NGT 1999 and 2005 77.3  0.3 Ref 77.2  0.3 Ref 75.8  0.7 Ref
Incident IFG 75.7  1.4 0.243 75.9  1.4 0.356 74.4  1.5 0.326
Incident IGT 74.2  1.0 0.003 74.4  1.0 0.007 73.1  1.2 0.009
Incident newly diagnosed diabetes 74.3  1.1 0.011 74.7  1.1 0.028 73.5  1.3 0.051
Data are marginal mean SEM. *Model 1: SF-36 dimensions adjusted for diabetes status, age, and sex. †Model 2: SF-36 dimensions adjusted for model 1 and BMI,
systolic blood pressure and total cholesterol. ‡Model 3: SF-36 dimensions adjusted for model 2 and smoking, known cardiovascular disease and medication for
hypertension or a lipid abnormality. Ref, referent.
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that HRF was impaired on all dimensions
of the HRF scale compared with those
with NGT.
A consistent finding through the lim-
ited number of studies to assess HRF
across the spectrum of glycemic values is
that the decline in HRF is related to the
physical component of the SF-36, with
mixed results shown for the mental com-
ponent (3–5). A similar pattern has been
observed in research focused on HRF
with adiposity, coronary heart disease,
and insulin resistance (18–22). It is likely
that inactivity is a risk factor for both im-
paired HRF and impaired glucose metab-
olism and type 2 diabetes. In terms of
physical functioning, metabolic abnor-
malities underpinning type 2 diabetes
have been associated with reduced mus-
cle strength and impaired HRF in the do-
main of physical functioning. In a large
prospective study assessing body weight
and HRF, the study showed that after 4
years, weight gain was associated with de-
creased physical functioning and vitality
and increased bodily pain, regardless of
baseline weight status (23). In contrast,
those who lost weight had increased
physical functioning and vitality and de-
creased bodily pain. Identification of
individuals with mild to moderately im-
paired physical functioning could pro-
vide some prognostic information on the
future risk of diabetes very early in the
disease process. This finding is particu-
larly relevant as it is well established that
there is a strong link between physical in-
activity, obesity, and type 2 diabetes.
Given that improved HRF among those
with diabetes is known to improve self-
management and lead to lifestyle changes,
crucial for improved glycemic control,
HRF across the continuum of glycemic
values requires further investigation (24).
The findings from this study raise
questions about the casual pathways and
mechanisms involved in diabetes onset
and its progression related to HRF and
other salient psychosocial determinants.
For example, the presence of reduced
HRF in the years preceding disease onset
may suggest that the process is mediated
through the behavioral pathways known
to reduce HRF and act as risk factors for
chronic disease (e.g., increased sedentary
behavior as a result of reduced function-
ing). Although data from epidemiological
cohort studies have previously refuted the
suggestion that associations between psy-
chosocial factors and disease risk are
likely to be mediated through behavioral
pathways (25), further research is re-
quired into the psychosocial determi-
nants of chronic disease onset to provide a
clearer picture of the associated casual
pathways.
The current study has limitations.
The follow-up response rate for the Aus-
Diab study was limited, and this may have
led to an underestimation of the associa-
tion between quality-of-life measures and
glucose metabolism. The results of this
study suggest there is an independent as-
sociation between impaired HRF and
IFG, IGT, and NDM. It should be noted
that this association is likely to be bidirec-
tional. For example, among those with
known diabetes, the presence of compli-
Figure 1—A: PCS scale of AusDiab study participants according to diabetes status at the 5-year
follow-up. B: MCS scale of AusDiab study participants according to diabetes status at the 5-year
follow-up. Error bars represent 95% CI. Model 1 was adjusted for age and sex; model 2 was
adjusted for age, sex, BMI, systolic blood pressure, and total cholesterol; and model 3 was adjusted
for age, sex, BMI, systolic blood pressure, total cholesterol, current treatment for hypertension or
lipid abnormalities, and known CVD. The PCS is a summary of physical functioning, role-
physical, bodily pain, and general health. The MCS is a summary measure of vitality, social
functioning, role-emotional, and mental health. NDM, newly diagnosed diabetes.
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cations is associated with a reduced HRF
and the greater the number or severity of
complications, the greater the decrease in
HRF. This could be a consequence of hav-
ing a number of complications decreasing
quality of life or conversely the impact of
poor HRF on diabetes control.
In summary, these findings show that
IFG, IGT, and newly diagnosed diabetes
are associated with reduced HRF and that
this is evident before the onset of these
conditions, independent of known CVD.
This is an important finding. If future
health promotion campaigns are to effec-
tively target those at high risk of develop-
ing diabetes, an understanding of the
process of declining health before the on-
set of the disease is essential.
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